Be the first person to write a business review for Anadys Pharmaceuticals, Inc.

Anika Therapeutics, Inc. company was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans; and AMVISC, AMVISC Plus, STAARVISC-II, and ShellGel that are injectable ophthalmic viscoelastic HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. It also provides HYVISC, an HA product used in the treatment of equine osteoarthritis; INCERT, an HA based anti-adhesive for surgical applications; and ORTHOVISC mini, a treatment for osteoarthritis targeting small joints. In addition, the company offers MONOVISC, a single-injection osteoarthritis product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis; and ELEVESS, which is designed as a family of aesthetic dermatology products for facial wrinkles, scar remediation, and lip augmentation. Further, it involves in the research and development of joint health related products, such as a single-injection treatment product that uses a non-animal source HA. Anika Therapeutics, Inc. offers its products in the United States, as well as in Canada, Europe, Turkey, the Middle East, and Asia through representatives, agents, and distributors.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.